Ascelia Pharma AB - ESG Rating & Company Profile powered by AI
This ESG assessment for Ascelia Pharma AB indicates the company's reporting of the UN Sustainable Development Goals. Detailed Sustainability analysis of Ascelia Pharma AB can be reached by logging in. The page is a zero-cost Environmental, Social and Governance analysis for Ascelia Pharma AB.
Ascelia Pharma AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 5.3, social score of 8.0 and governance score of 8.0.
7.1
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
217 | Takara Bio Inc | 7.2 | High |
217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
224 | Ascelia Pharma AB | 7.1 | High |
224 | Celularity Inc | 7.1 | High |
224 | Bilcare Ltd | 7.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Ascelia Pharma AB have an accelerator or VC vehicle to help deliver innovation?
Does Ascelia Pharma AB disclose current and historical energy intensity?
Does Ascelia Pharma AB report the average age of the workforce?
Does Ascelia Pharma AB reference operational or capital allocation in relation to climate change?
Does Ascelia Pharma AB disclose its ethnicity pay gap?
Does Ascelia Pharma AB disclose cybersecurity risks?
Does Ascelia Pharma AB offer flexible work?
Does Ascelia Pharma AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Ascelia Pharma AB disclose the number of employees in R&D functions?
Does Ascelia Pharma AB conduct supply chain audits?
Does Ascelia Pharma AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Ascelia Pharma AB conduct 360 degree staff reviews?
Does Ascelia Pharma AB disclose the individual responsible for D&I?
Does Ascelia Pharma AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Ascelia Pharma AB disclose current and / or historical scope 2 emissions?
Does Ascelia Pharma AB disclose water use targets?
Does Ascelia Pharma AB have careers partnerships with academic institutions?
Did Ascelia Pharma AB have a product recall in the last two years?
Does Ascelia Pharma AB disclose incidents of discrimination?
Does Ascelia Pharma AB allow for Work Councils/Collective Agreements to be formed?
Has Ascelia Pharma AB issued a profit warning in the past 24 months?
Does Ascelia Pharma AB disclose parental leave metrics?
Does Ascelia Pharma AB disclose climate scenario or pathway analysis?
Does Ascelia Pharma AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Ascelia Pharma AB disclose the pay ratio of women to men?
Does Ascelia Pharma AB support suppliers with sustainability related research and development?
Does Ascelia Pharma AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Ascelia Pharma AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Ascelia Pharma AB involved in embryonic stem cell research?
Does Ascelia Pharma AB disclose GHG and Air Emissions intensity?
Does Ascelia Pharma AB disclose its waste policy?
Does Ascelia Pharma AB report according to TCFD requirements?
Does Ascelia Pharma AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Ascelia Pharma AB disclose energy use targets?
Does Ascelia Pharma AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Ascelia Pharma AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Ascelia Pharma AB
These potential risks are based on the size, segment and geographies of the company.
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.